Navigation Links
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
Date:12/20/2007

cialization of the product and Nektar will be responsible for the technology development used in the product including the provision of clinical and commercial PEG reagents. Nektar PEGylation technology has already been successfully applied to eight marketed products in the United States and Europe.

About Nektar Advanced PEGylation Technology

Nektar Advanced PEGylation has the potential to improve the safety and efficacy of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It is based on the use of non-toxic polyethylene glycol (PEG) polymers, which can be attached to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs and is used in eight marketed products in the U.S. and Europe today.

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and enable differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar pulmonary and PEGylation technology, expertise, manufacturing capabilities and know-how have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements and the terms of the agreement between Baxter and Nektar. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) clinical trials are long, expensive and uncertain processes and the successful completion of future clinical development activities will be required in order for Nektar to realize future development milestone paymen
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... /PRNewswire-FirstCall/ -- HealthSouth,Corporation...previously,publicized investor meeting in New York...08 at 8:30 a.m. EST at the Grand Hyatt New York, l...ng is as follows:, 8:00 a.m. Continental Brea...f Executive Officer -- HealthSouth Ov...
(Date:10/6/2008)...y personnel and their family members can take,anon...nts, BOSTON, Oct. 6 /PRNewswire-USNewswire/ -- Mi...ers and their families that are unique and,difficu...tances matters get,worse and one problem can trigg...wise to check things out to see what is really hap...
(Date:10/6/2008)... at the University of California, San Diego School...upplements bolsters production of a protective che...vent skin infections that are a common result of a..., The study led by Richard Gallo, M.D., Ph.D., ... Dermatology at the UCSD School of Medicine and th...
(Date:10/6/2008)...ire/ -- A special supplement of the Oct. 15,journa... low- and,middle-income countries to implement bre...ommon disease among women worldwide., "Guidelines...l -,Implementation" developed by the Breast Health... of resource allocation -- based on countries,ove...
Breaking Medicine News(10 mins):Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3
...udies have shown that mapping the brain areas preo... of tumor surgery. A study that is to appear in t...stematically mapping the motor// and language area...c resonance imaging (fMRI), could help the surgeon...
...searchers from the University of Georgia have cond...to how the T cells in the body react to parasitic ...// A study led by scientists at the University of...d in the online journal PLOS Pathogens, which is a...
... Researchers believe that the transfusions of bloo...e the number of deaths due to bird flu in case of ...during the Spanish flu pandemic of 1918-1920, the ...ns from people who had recovered had improved the ...
...venscourt Park Hospital, which was described as be...d for the lack of patients. Hammersmith Hospitals ...02. At that time ministers had predicted that the...ve surgery. Ravenscourt Park, which had six theatr...
Other Medicine News:Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 2Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 3
(Date:10/6/2008)... that drinking polyphenol-rich 100% Concord grape,... energy intake or body,weight, CONCORD, Mass., Oc...olyphenol-rich Concord grape juice did not cause s...anges in appetite and was shown to reduce waist,ci... 49th Annual Meeting of,the American College of Nu...
(Date:10/3/2008)...B-Raf Kinase Inhibitors for Cancer Treatments, IN...swire-FirstCall/ --,Eli Lilly and Company (NYSE: ..., LLC today announced that the two companies have ...ng agreement related to,Deciphera,s preclinical B-...ntial oncology therapeutics., The collaboration w...
(Date:10/2/2008)...ober 2 /- Calabar AB announced today,...mia ("dry mouth"),patients has been initiated. Spe...h patients between the ages of 20 to 75. The objec...on in a succeeding Phase III efficacy,study., Xal...hibitor,physostigmine. It is administered locally ...
(Date:10/1/2008)...tic potential of Amylin,s integrated neurohormonal...apy, SAN DIEGO, Oct. 1 /- ...y announced that new data for its pipeline obesity...cientific Meeting of The,Obesity Society in Phoeni...g is one of the largest and most comprehensive sci...
Breaking Medicine Technology:Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology 2086 1CerviLenz Receives JumpStart Investment 19559 1CerviLenz Receives JumpStart Investment 19559 2CerviLenz Receives JumpStart Investment 19559 3Dont Wait for the Election to Plan Your Long Term Healthcare Insurance Leader Advises 19556 1Dont Wait for the Election to Plan Your Long Term Healthcare Insurance Leader Advises 19556 2Oklahoma Students Win Be Smart Dont Start 21 Contest 19552 1Oklahoma Students Win Be Smart Dont Start 21 Contest 19552 2
...y manufactured radiation protective eyewear can el...r high quality frames and materials offer the best... lenses are made of Schott RS-520 (SF-6 leaded) op...Glasses are offered with lead impregnated side shi...
Uvex Patriot Frame
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields.
Medicine Products: